celestial trial: second-line cabozantinib’s value in hcc
Published 6 years ago • 296 plays • Length 2:33Download video MP4
Download video MP3
Similar videos
-
6:39
emerging second-line therapies in hcc
-
2:45
sequencing with cabozantinib in advanced hcc
-
8:40
advanced hcc: celestial trial
-
1:36
cabozantinib in patients with hcc refractory to checkpoint inhibitors
-
6:00
clinical rationale for cabozantinib in hcc
-
1:46
results from the celestial trial for patients with advanced hcc
-
5:10
understanding the resorce data in second-line hcc
-
5:27
second-line systemic therapy in hcc
-
0:54
dr. singal on the fda approval of cabozantinib in hcc
-
5:48
second-line therapy in advanced hcc
-
2:58
phase ii trial of cabozantinib for patients with hcc previously treated with io
-
1:18
dr. abou-alfa on the fda approval of cabozantinib in hcc
-
3:20
choosing a tki in second-line metastatic hcc
-
3:56
comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma
-
4:24
optimal use of second-line tkis in hepatocellular carcinoma
-
4:58
emerging c-met inhibitors in hcc
-
4:11
second-line treatment for hepatocellular carcinoma
-
6:30
cabozantinib: the meteor trial